Characterization of genomic profiling of Mexican women with breast cancer using EndoPredict

• Published in: Cancer treatment and research communications 2024-11, Vol.42, p.100851, Article 100851
• Main Authors: Sandoval, Diana Carolina Correa, Murguia, Jose Luis Guzman, Nieto, Diego Alberto Guajardo
• Format: Article
• Language: English
• Subjects: Breast neoplasm; Endopredict; Genomics; Mexico; Women
• ISSN: 2468-2942; 2468-2942
• DOI: 10.1016/j.ctarc.2024.100851

•Groundbreaking insights into breast cancer in Mexico: our study offers groundbreaking insights into the landscape of breast cancer in Mexico, addressing the surge in incidence and mortality rates, while uncovering unique challenges such as delayed diagnoses and limited treatment access, particularly among underserved populations.•Advanced genomic profiling with endopredict Test: utilizing the cutting-edge endopredict test, we conducted comprehensive genomic profiling of Mexican women diagnosed with stage I-III breast cancer. This innovative approach provides unparalleled biological insights, guiding precise treatment decisions and improving patient outcomes.•Revolutionizing diagnostic Paradigms: by investigating the correlation between genomic expression and immunohistochemistry within our Mexican breast cancer cohort, we challenge traditional diagnostic paradigms. Our findings underscore the reliability of advanced molecular testing over conventional methods, revolutionizing the approach to breast cancer diagnosis and treatment.•Personalized medicine at its Best: through rigorous risk stratification based on immunohistochemistry and molecular testing, our study empowers personalized medicine. We demonstrate the ability to tailor treatment strategies to individual patient needs, optimizing therapeutic interventions and ultimately enhancing survival rates.•Global implications and future Directions: our research not only advances the understanding of breast cancer within the Mexican population but also holds global significance. By contributing valuable data to the evolving landscape of breast cancer research, we pave the way for future studies aimed at optimizing diagnostic and prognostic tools for diverse populations worldwide. In the context of rising breast cancer incidence and mortality rates in Mexico, our study delves into the genomic landscape of Mexican women diagnosed with stage I-III breast cancer. Employing the EndoPredict test for genomic analysis, our retrospective, cross-sectional study explores correlations between genomic expression and immunohistochemistry (IHC). Among 50 female patients, risk stratification by IHC revealed 50 % as high risk and 50 % as low risk, with notable clinical and histological distinctions between the two groups. High-risk samples exhibited larger tumors, higher histological grades, and more positive lymph nodes. Immunohistochemistry results displayed a moderate concordance (kappa Cohen´s 0.48) with the EndoPredict